Academic Journal
Epigenetic aging biomarkers in dietary geroscience: feasibility, participant perceptions, and trial design considerations.
| Τίτλος: | Epigenetic aging biomarkers in dietary geroscience: feasibility, participant perceptions, and trial design considerations. |
|---|---|
| Συγγραφείς: | Reynolds LM; Department of Epidemiology and Prevention, Division of Public Health Sciences, Center for Precision Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Lindsay.reynolds@wfusm.edu., Howard TD; Department of Biochemistry, Center for Precision Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Langefeld CD; Department of Biostatistics and Data Science, Division of Public Health Sciences, Center for Precision Medicine, and Center for Artificial Intelligence Research, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Vitolins MZ; Department of Epidemiology and Prevention, Division of Public Health Sciences, Center for Precision Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA. |
| Πηγή: | GeroScience [Geroscience] 2026 Oct; Vol. 48 (5), pp. 6251-6262. Date of Electronic Publication: 2026 Jul 29. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101686284 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2509-2723 (Electronic) Linking ISSN: 25092723 NLM ISO Abbreviation: Geroscience Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Cham : Springer International Publishing, [2017]- |
| Ιατρικοί όροι (MeSH): | Aging*/genetics , Metabolic Syndrome*/diet therapy , Metabolic Syndrome*/genetics , Geroscience*/methods , Epigenesis, Genetic*, Olive Oil/administration & dosage ; Humans ; Aged ; Middle Aged ; Female ; Feasibility Studies ; Male ; Biomarkers ; Aged, 80 and over ; Pilot Projects ; Nuts ; Research Design |
| Περίληψη: | Targeting biological processes of aging is a central goal of geroscience; however, limited data exist regarding the feasibility of incorporating biological aging biomarkers into dietary intervention trials. We conducted a pilot feasibility study among 34 adults aged 48-81 years with metabolic syndrome, a condition associated with elevated risk of age-related cardiometabolic disease and advanced biological aging. Participants consumed 1 oz of tree nuts and two tablespoons of extra virgin olive oil daily for 4 weeks. The primary objectives were to evaluate feasibility, adherence, and participant acceptability of epigenetic aging assessments. Exploratory outcomes included DunedinPACE, a measure of the pace of aging, and AgeAccelGrim, a measure of biological age relative to chronological age. At baseline, all participants exhibited a faster pace of biological aging than average as assessed by DunedinPACE, supporting metabolic syndrome as a promising target population for geroscience interventions. Adherence to the dietary intervention exceeded 95%, and most participants reported willingness to participate in a similar longer-term trial. Participants expressed a strong interest in learning their biological age and indicated that evidence of slowed aging would motivate sustained dietary change. No significant changes in epigenetic aging were observed over the 4-week intervention. These findings demonstrate the feasibility and acceptability of incorporating epigenetic aging biomarkers into dietary intervention research and suggest that biological aging measures may serve not only as surrogate outcomes but also as tools to support participant engagement. The results also support metabolic syndrome as a relevant population for dietary geroscience trials and provide practical guidance for designing longer-term studies evaluating whether dietary interventions can slow biological aging and promote healthy longevity. ClinicalTrials.gov Identifier: NCT04361617 (date of registration: 04-23-2020). (© 2026. The Author(s).) |
| Competing Interests: | Declarations. Conflict of interest: The authors declare no competing interests. |
| References: | Am J Clin Nutr. 2024 Nov;120(5):1143-1155. (PMID: 39510725) Nat Commun. 2025 Dec 16;16(1):11164. (PMID: 41402269) Aging Cell. 2021 Oct;20(10):e13439. (PMID: 34535961) Nutrients. 2026 Feb 01;18(3):. (PMID: 41683294) Diabetes Care. 2023 Jan 1;46(1):28-37. (PMID: 36162007) Nat Aging. 2023 Mar;3(3):248-257. (PMID: 37118425) Clin Epigenetics. 2025 May 7;17(1):78. (PMID: 40336042) Am J Clin Nutr. 2022 Jan 11;115(1):171-179. (PMID: 34637497) Metabolism. 2014 Jul;63(7):903-11. (PMID: 24931280) Nat Commun. 2023 Aug 19;14(1):5038. (PMID: 37598227) Int J Obes (Lond). 2024 Jun;48(6):778-787. (PMID: 38273034) Nutrients. 2021 Jul 09;13(7):. (PMID: 34371858) Biostatistics. 2007 Jan;8(1):118-27. (PMID: 16632515) J Clin Med. 2022 Aug 10;11(16):. (PMID: 36012914) Aging (Albany NY). 2018 Apr 18;10(4):573-591. (PMID: 29676998) J Acad Nutr Diet. 2024 Nov;124(11):1419-1430.e3. (PMID: 38215906) Aging Cell. 2024 Jul;23(7):e14170. (PMID: 38638005) CMAJ. 2014 Nov 18;186(17):E649-57. (PMID: 25316904) Cell. 2014 Nov 6;159(4):709-13. (PMID: 25417146) Molecules. 2016 Jan 29;21(2):163. (PMID: 26840281) Int J Behav Nutr Phys Act. 2016 Jun 14;13:67. (PMID: 27297426) Commun Med (Lond). 2026 Mar 27;6(1):. (PMID: 41896267) J Gerontol A Biol Sci Med Sci. 2025 Aug 23;80(9):. (PMID: 40577096) J Am Coll Cardiol. 2012 Feb 14;59(7):635-43. (PMID: 22322078) J Gerontol A Biol Sci Med Sci. 2019 Jan 1;74(1):91-98. (PMID: 30256915) Biogerontology. 2018 Dec;19(6):447-459. (PMID: 30054761) Biomark Res. 2026 Mar 6;14(1):. (PMID: 41792861) Geroscience. 2020 Apr;42(2):687-701. (PMID: 31981007) Clin Nutr. 2017 Oct;36(5):1301-1309. (PMID: 27665232) Circulation. 2009 Oct 20;120(16):1640-5. (PMID: 19805654) Physiology (Bethesda). 2023 Jan 1;38(1):0. (PMID: 36125787) Elife. 2022 Jan 14;11:. (PMID: 35029144) Am J Clin Nutr. 2022 Jan 11;115(1):163-170. (PMID: 34134146) Gerontology. 2020;66(2):209-210. (PMID: 31505500) Curr Opin Clin Nutr Metab Care. 2016 Jan;19(1):5-11. (PMID: 26560521) Ann N Y Acad Sci. 2022 Jan;1507(1):70-83. (PMID: 34498278) Proc Nutr Soc. 2023 Sep;82(3):359-369. (PMID: 37475596) Food Chem. 2026 Sep 15;523:149828. (PMID: 42364470) Biomedicines. 2024 Jan 22;12(1):. (PMID: 38275413) N Engl J Med. 2018 Jun 21;378(25):e34. (PMID: 29897866) Bioinformatics. 2014 Feb 01;30(3):428-30. (PMID: 24336642) Biogerontology. 2024 Jun;25(3):423-431. (PMID: 37968337) Nat Aging. 2025 Mar;5(3):376-385. (PMID: 39900648) Aging (Albany NY). 2019 Jan 21;11(2):303-327. (PMID: 30669119) J Nutr Health Aging. 2025 Jul;29(7):100602. (PMID: 40505553) Nat Rev Endocrinol. 2022 Jul;18(7):433-448. (PMID: 35513492) Curr Biol. 2012 Sep 11;22(17):R741-52. (PMID: 22975005) J Acad Nutr Diet. 2012 Aug;112(8):1134-7. (PMID: 22704899) J Clin Med. 2019 Dec 01;8(12):. (PMID: 31805696) Nat Med. 2026 Mar;32(3):1012-1022. (PMID: 41803341) Cell. 2023 Aug 31;186(18):3758-3775. (PMID: 37657418) PLoS One. 2012;7(8):e43134. (PMID: 22905215) Pharmacol Res. 2012 Jun;65(6):577-83. (PMID: 22449789) |
| Grant Information: | UL1 TR001420 United States TR NCATS NIH HHS; UL1TR001420 United States TR NCATS NIH HHS |
| Contributed Indexing: | Keywords: Biological aging; Dietary intervention; Epigenetic aging; Extra virgin olive oil; Geroscience; Mediterranean diet; Metabolic syndrome; Tree nuts |
| Molecular Sequence: | ClinicalTrials.gov NCT04361617 |
| Substance Nomenclature: | 0 (Biomarkers) 0 (Olive Oil) |
| Entry Date(s): | Date Created: 20260729 Date Completed: 20260923 Latest Revision: 20260926 |
| Update Code: | 20260926 |
| PubMed Central ID: | PMC13601483 |
| DOI: | 10.1007/s11357-026-02443-0 |
| PMID: | 42527728 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!